Actively Recruiting
Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer
Led by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2025-05-14
30
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single arm, single cencer, phase II clinical trial. This study aims to evaluate the efficacy and safety of Cadonilimab combined with S-1 or capecitabine as a second-line treatment for advanced pancreatic cancer.
CONDITIONS
Official Title
Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed written informed consent
- Age between 18 and 80 years, female or male
- Histopathologically confirmed pancreatic ductal adenocarcinoma
- Locally advanced pancreatic cancer with no distant metastasis and specific tumor involvement criteria
- Previously received standard first-line anti-tumor treatment
- At least one measurable lesion as per RECIST 1.1
- ECOG performance status of 0 or 1
- Expected survival time greater than 3 months
- Adequate organ function
You will not qualify if you...
- Malignant diseases other than pancreatic cancer diagnosed within 5 years before the first dose (except certain skin cancers)
- Participation in other interventional clinical research or use of research drugs/devices within 4 weeks before the first dose
- Active autoimmune disease
- History of allogeneic organ or hematopoietic stem cell transplantation
- Allergy to cadonilimab, S-1, capecitabine, or their excipients
- Unrecovered toxicity or complications from previous interventions
- History of HIV infection
- Active hepatitis B or C infection
- Pregnant or breastfeeding women
- Any severe or uncontrolled systemic disease
- Active pulmonary tuberculosis
- Mental disorders preventing cooperation with treatment
- Uncontrolled infection
- Investigator assessment of inability to complete the trial or unsuitability for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai General Hospital
Shanghai, Shanghai Municipality, China, 200040
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here